新・血栓止血血管学　検査と診療

出版社： 金芳堂
著者：
発行日： 2015-10-20
分野： 臨床医学：内科  >  血液
ISBN： 9784765316514
シリーズ： 新・血栓止血血管学
電子書籍版： 2015-10-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

6,600 円(税込)

購入する

目次

  • 新・血栓止血血管学　検査と診療

    ―目次―

    1部　出血病と血栓症の検査・診断
    　1．血栓止血関連検査：オーバービュー
    　2．血小板系検査
    　3．凝固系検査・抗凝固検査
    　4．線溶検査
    　5．血栓・血管・血流の包括的検査
    　6．凝固波形解析
    　7．静脈血栓塞栓症の検査診断
    　8．血栓症の分子疫学とSNPs
    　9．止血・血栓症に関連するOmics網羅的解析の動向
    　10．遺伝子組換え動物

    2部　出血病と血栓症の治療
    　11．出血病と血栓症の治療：オーバービュー
    　12．血液製剤
    　13．輸血のパラダイムシフト
    　14．新規経口抗凝固薬（DOACs）：オーバービュー
    　15．心房細動とDOACs
    　16．静脈血栓塞栓症とDOACs
    　17．DOACsと凝固検査
    　18．血栓溶解療法の進歩
    　19．虚血性脳血管障害の抗血小板療法
    　20．抗血小板併用療法
    　21．冠動脈疾患の治療：ステント血栓症を含む
    　22．血栓症の血管内治療・外科的治療
    　23．血栓止血領域における抗体医薬
    　24．iPS細胞の医療応用

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1部 出血病と血栓症の検査・診断

P.7 掲載の参考文献
1) 村田満. 出血性疾患の診断アプローチ. In : 柴田昭, 他編. エッセンシャル血液病学. 第5版. 東京 : 医歯薬出版, 2005 ; 221-226.
 
2) Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool : a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010 ; 8(9) : 2063-2065.
 
P.17 掲載の参考文献
1) 尾崎由基男, 井上克枝, 井上修. 血小板機能の新しい展開. 血栓以外の役割. 臨床病理 2012 ; 60 : 52-58.
Medical*Online
2) Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962 ; 194 : 927-929.
PubMed
3) Hosokawa K, Ohnishi T, Kondo T, Fukasawa M, Koide T, Maruyama I, Tanaka KA. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost 2011 ; 9 : 2029-2037.
PubMed
4) Gorog DA, Fuster V. Platelet function tests in clinical cardiology : unfulfilled expectations. J Am Coll Cardiol 2013 ; 61 : 2115-2129.
PubMed
5) Janssen PW, ten Berg JM. Platelet function testing and tailored antiplatelet therapy. J Cardiovasc Transl Res 2013 ; 6 : 316-328.
PubMed
6) Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the standardization of light transmission aggregometry : a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. Journal of Thrombosis and Haemostasis 2013 ; 11 : 1183-1189.
 
7) Femia EA, Pugliano M, Podda G, et al. Comparison of different procedures to prepare platelet-rich plasma for studies of platelet aggregation by light transmission aggregometry. Platelets. 2012 ; 23(1) : 7-10.
PubMed
8) Christie D, Avari T, Carrington L, et al. Platelet function testing by aggregometry : approved guideline. Clinical and Laboratory Standards Institute 2008 ; 28(31) : 1-45.
 
9) Castilloux JF, Moffat KA, Liu Y, et al. A prospective cohort study of light transmission platelet aggregometry for bleeding disorders : is testing native plateletrich plasma non-inferior to testing platelet count adjusted samples? Thromb Haemost 2011 ; 106(4) : 675-82.
 
10) 冨山佳昭.【血栓症に関するQ&A(PART6)】 検査・診断血小板凝集能の標準化に対して, 国内, 国外でどのような取り組みをしていますか. 血栓と循環 2011 : 19 : 65-66.
 
11) Harrison P, Mackie I, Mumford A, et al. British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011 ; 155 : 30-44.
PubMed
12) Femia EA, Pugliano M, Podda G, et al. Comparison of different procedures to prepare platelet-rich plasma for studies of platelet aggregation by light transmission aggregometry. Platelets 2012 ; 23 : 7-10.
PubMed
13) Lawrie AS, Kobayashi K, Lane PJ, et al. The automation of routine light transmission platelet aggregation. Int J Laboratory Hematol 2014 ; 36 : 431-438.
 
14) Lordkipanidze M, Pharand C, Nguyen TA, et al. Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008 ; 29 : 2877-2885.
PubMed
15) Aradi D, Storey RF, Komocsi A, et al. Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014. ; 35 : 209-215.
 
16) Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors : collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015 ; 36(27) : 1762-1771.
PubMed
17) Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance : an unintended consequence of enteric coating aspirin. Circulation 2013 ; 127 : 377-385.
PubMed
18) Ohmori T, Yatomi Y, Nonaka T, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity : involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006 ; 4 : 1271-1278.
PubMed
19) Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009 ; 302 : 849-857.
PubMed
20) Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009 ; 360 : 354-362.
PubMed
21) Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than highdose (150-mg) clopidogrel : the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011 ; 4 : 403-410.
PubMed
22) Price MJ, Berger PB, Teirstein PS, et al. GRAVITAS Investigators. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention : the GRAVITAS randomized trial. JAMA 2011 ; 305 : 1097-1105.
PubMed
23) Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and longterm cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011 ; 306 : 1215-1223.
PubMed
24) Collet JP, Cuisset T, Range G, et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012 ; 367 : 2100-2109.
PubMed
25) Angiolillo DJ, Ferreiro JL, Price MJ, et al. Platelet function and genetic testing. J Am Coll Cardiol 2013 ; 62 : S21-S31.
PubMed
26) Tantry US, Bonello L, Aradi D, et al. Working Group on On-Treatment Platelet R. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013 ; 62 : 2261-2273.
 
27) Kerneis M, Silvain J, Abtan J, et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv 2013 ; 6 : 158-165.
PubMed
P.24 掲載の参考文献
1) Aggeler PM, White SG, Glendening MB, et al. Plasma thromboplastin component (PTC) deficiency : a new disease resembling hemophilia. Proc Soc Exp Biol Med 1952 ; 79(4) : 692-694.
PubMed
2) Ratnoff OD, Margolius A Jr. Hageman trait : an asymptomatic disorder of blood coagulation. Trans Assoc Am Physicians 1955 ; 68 : 149-154.
PubMed
3) Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953 ; 82(1) : 171-174.
PubMed
4) Stenflo J, Fernlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 1974 ; 71 : 2730-2733.
PubMed
5) Rosing J, Tans G, Govers-Riemslag JW, et al. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem. 1980 ; 255(1) : 274-283.
PubMed
6) Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964 ; 145 : 1310-1312.
PubMed
7) Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin : A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961 ; 36 : 212-219.
PubMed
8) 新井盛大 : 凝固系検査. In : 一瀬白帝 (編) : 図説 血栓・止血・血管学 血栓症制圧のために. 東京 : 中外医学社. 2005 : 757-763.
 
9) Davie EWl, Fujikawa K, Kisiel W. The coagulation cascade : initiation, maintenance, and regulation. Biochemistry 1991 ; 30(43) : 10363-10370.
 
10) 特集 : POCT 対応機器・試薬の現状と将来 ; 臨床化学 2015 ; 44 : 95-102.
 
P.34 掲載の参考文献
1) 浦野哲盟, 柴山知子, 鈴木優子. ユーグロブリンクロット溶解時間. 検査と技術 2011 ; 39 : 86-91.
 
2) Urano T, Sumiyoshi K, Pietraszek MH, et al. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 1991 ; 66 : 474-478.
 
3) Madoiwa S, Komatsu N, Mimuro J, et al. Developmental expression of plasminogen activator inhibitor-1 associated with thrombopoietin-dependent megakaryocytic differentiation. Blood 1999 ; 94 : 475-482.
PubMed
4) Madoiwa S, Nunomiya S, Ono T, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol 2006 ; 84 : 398-405.
PubMed
5) Alessi MC, Bastelica D, Morange P, et al. Plasminogen activator inhibitor 1, transforming growth factorbeta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000 ; 49 : 1374-1380.
PubMed
6) Aoki N. Discovery of alpha2-plasmin inhibitor and its congenital deficiency. J Thromb Haemost 2005 ; 3 : 623-631.
PubMed
7) Miura O, Hirosawa S, Kato A, et al. Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence. J Clin Invest 1989 ; 83 : 1598-1604.
PubMed
8) Madoiwa S, Someya T, Hironaka M, et al. Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis. Thrombosis research 2007 ; 119 : 229-240.
PubMed
9) Oshiro A, Yanagida Y, Gando S, et al. Hemostasis during the early stages of trauma : comparison with disseminated intravascular coagulation. Critical care 2014 ; 18 : R61.
 
10) Francis CW, Marder VJ, Barlow GH. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure. J Clin Invest 1980 ; 66 : 1033-1043.
 
11) 松田道生. フィブリノゲンの誘導体, とくに可溶性フィブリンとDダイマーについて (その2) Dダイマーについて. 血栓止血誌 1997 ; 8 : 204-211.
 
12) Righini M, Perrier A, De Moerloose P, et al. D-Dimer for venous thromboembolism diagnosis : 20 years later. J Thromb Haemost 2008 ; 6 : 1059-1071.
PubMed
13) Madoiwa S, Kitajima I, Ohmori T, et al. Distinct reactivity of the commercially available monoclonal antibodies of D-dimer and plasma FDP testing to the molecular variants of fibrin degradation products. Thromb Res 2013 ; 132 : 457-464.
 
14) Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism : a systematic review. Ann Int Med 2004 ; 140 : 589-602.
PubMed
15) Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Eng J Med 2003 ; 349 : 1227-1235.
 
16) Righini M, Kamphuisen PW, Le Gal G. Age-adjusted D-dimer cutoff levels and pulmonary embolism?reply. JAMA 2014 ; 312 : 557-558.
PubMed
17) Kohno I, Inuzuka K, Itoh Y, et al. A monoclonal antibody specific to the granulocyte-derived elastase-fragment D species of human fibrinogen and fibrin : its application to the measurement of granulocyte-derived elastase digests in plasma. Blood 2000 ; 95 : 1721-1728.
 
18) Kamikura Y, Wada H, Sase T, et al. Hemostatic abnormalities and leukocyte activation caused by infection in patients with malignant lymphoma during chemotherapy. Thromb Res 2006 ; 117 : 671-679.
PubMed
19) Gando S, Hayakawa M, Sawamura A, et al. The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation. Thromb Res 2007 ; 121 : 67-73.
PubMed
20) Watanabe H, Madoiwa S, Sekiya H, et al. Predictive blood coagulation markers for early diagnosis of venous thromboembolism after total knee joint replacement. Thromb Res 2011 ; 128 : e137-e143.
PubMed
21) Plow EF, Gramse M, Havemann K. Immunochemical discrimination of leukocyte elastase from plasmic degradation products of fibrinogen. J Lab Clin Med 1983 ; 102 : 858-869.
PubMed
22) Madoiwa S, Tanaka H, Nagahama Y, et al. Degradation of cross-linked fibrin by leukocyte elastase as alternative pathway for plasmin-mediated fibrinolysis in sepsis-induced disseminated intravascular coagulation. Thromb Res 2011 ; 127 : 349-355.
PubMed
23) Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation : its correlation with development of renal failure. Blood 2006 ; 107 : 528-534.
PubMed
P.42 掲載の参考文献
1) Hosokawa K, Ohnishi T, Fukasawa M, et al. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res 2012 ; 83(2) : 154-161.
PubMed
2) Hosokawa K, Ohnishi T, Sameshima H, et al. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost 2013 ; 109(1) : 102-111.
PubMed
3) Ogawa S, Hosokawa K, Tanaka KA. Influences of hemodilution and anticoagulation on antiplatelet P2Y12 therapy : in vitro whole blood perfusion model. J Cardiothorac Vasc Anesth 2013 ; 27(6) : e69-e71.
 
4) Yong AS, Pennings GJ, Chang M, et al. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel. Blood 2011 ; 117(1) : 11-20.
PubMed
5) Hosokawa K, Ohnishi T, Kondo T, et al. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost 2011 ; 9(10) : 2029-2037.
 
6) Ogiwara K, Nogami K, Hosokawa K, et al. Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchipbased flow chamber system. Haemophilia 2015 ; 21(1) : 71-80.
PubMed
7) Goto S, Handa S. Coronary thrombosis. Effects of blood flow on the mechanism of thrombus formation. Jpn Heart J 1998 ; 39(5) : 579-596.
PubMed
8) Hosokawa K, Ohnishi T, Miura N, et al. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions. Thromb Res 2014 ; 133(1) : 66-72.
PubMed
9) Hosokawa K, Ohnishi T, Sameshima H, et al. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions : an in vitro flow chamber model. PLoS One. 2014 ; 9(1) : e86491.
 
10) Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2014 ; 366(1) : 9-19.
 
11) Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy : a randomized, double-blind, phase II trial. Eur Heart J 2011 ; 32(22) : 2781-2789.
PubMed
P.46 掲載の参考文献
1) Shima M, Thachil J, Nair SC, et al. Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost 2013 ; 11(7) : 1417-1420.
PubMed
2) Downey C, Kazmi R, Toh CH, et al. Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation. Br J Haematol 1997 ; 98(1) : 68-73.
PubMed
3) Downey C, Kazmi R, Toh CH, et al. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb Haemost 1998 ; 80(1) : 65-69.
PubMed
4) Paize F, Carrol E, Downey C, et al. Diagnostic efficacy of activated partial thromboplastin time waveform and procalcitonin analysis in pediatric meningococcal sepsis. Pediatric Critical Care Med 2011 ; 12(6) : e322-e329.
 
5) Toh CH, Samis J, Downey C, et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 2002 ; 100(7) : 2522-2529.
 
6) Collins PW, Macchiavello LY, Lewis SJ, et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006 ; 135(2) : 220-227.
 
7) Su Z, Braun PJ, Klemp KF, et al. Abnormal optical waveform profiles in coagulation assays from patients with antiphospholipid antibodies. Blood Coagul Fibrinolysis 2002 ; 13(1) : 7-17.
PubMed
8) Shima M, Matsumoto T, Fukuda K, et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII : C). Thromb Haemost 2002 ; 87(3) : 436-441.
PubMed
9) Matsumoto T, Shima M, Takeyama M. et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost 2006 ; 4(2) : 377-384.
PubMed
10) Kasuda S, Tanaka I, Shima M, et al. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors. Haemophilia 2004 ; 10(4) : 341-346.
PubMed
11) Yada K, Nogami K, Wakabayashi H, et al. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X. Thromb Haemost 2013 ; 109(6) : 1007-1015.
PubMed
12) Haku J, Nogami K, Matsumoto T, et al. Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis. J Thrombo Haemost 2014 ; 12(3) : 355-362.
 
13) Shirahata A, Fukutake K, Miyama J, et al. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial : 2nd report. Haemophilia 2013 ; 19(2) : 330-337.
 
14) Shima M. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Semin Hematol 2004 ; 41 (1 Suppl 1) : 125-131.
 
15) Matsumoto T, Nogami K, Shima M. Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors. J Thrombo Haemost 2014 ; 12(9) : 1503-1512.
 
P.58 掲載の参考文献
1) 日本循環器学会, 日本医学放射線学会, 日本胸部外科学会, 他. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告) : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版) Guidelines for the Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2009)
 
2) Zakai NA, McClure LA. Racial differences in venous thromboembolism. J Thoromb Haemost 2011 ; 9 : 1877-1882.
PubMed
3) Sakon M, Maehara Y, Yoshikawa H, et al. Incidence of venous thromboembolism following major abdominal surgery : a multicenter, prospective epidemiological study in Japan. J Thromb Haemost 2006 ; 4 : 581-586.
PubMed
4) Geerts WH, Bergqvist D, Pineo GF, et al ; American College of Chest Physicians. Prevention of venous thrombo-embolism : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 ; 133 (6 Suppl) : 381S-453S.
 
5) 日本整形外科学会肺血栓塞栓症/ 深部静脈血栓症(静脈血栓塞栓症) 予防ガイドライン改訂委員会編. 日本整形外科学会静脈血栓塞栓症予防ガイドライン, 南江堂, 2008.
 
6) Hamasaki N. Unmasking Asian thrombophilia : is APC dysfunction the real culprit? J Thromb Haemost 2012 ; 10 : 2016-2018.
PubMed
7) Hamasaki N, Kuma H, Tsuda H. Activated protein c anticoagulant system dysfunction and thrombophilia in Asia. Ann Lab Med 2013 ; 33 : 8-13.
PubMed
8) Yin T, Miyata T. Dysfunction of protein C anticoagulant system, main genetic risk factor for venous thromboembolism in Northeast Asians. J Thromb Thrombolysis 2014 ; 37 : 56-65.
PubMed
9) Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C : Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993 ; 90 : 1004-1008.
PubMed
10) Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994 ; 369 : 64-67.
PubMed
11) Liu HW, Kwong YL, Bourke C, et al. High incidence of thrombophilia detected in Chinese patients with venous thrombosis. Thromb Haemost 1994 ; 71, 416-419.
PubMed
12) Shen MC, Lin JS, Tsay W. High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Thromb Res 1997 ; 87 : 377-385.
PubMed
13) Tsuda H, Hattori S, Tanabe S, et al. Ann Clin Biochem 1999 ; 36 : 423-432.
PubMed
14) Kinoshita S, Iida H, Inoue S, et al. Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem 2005 ; 38 : 908-915.
PubMed
15) Hamasaki N, Kanaji T : Clinical Role of Protein S Deficiency in Asian Population. In : Tanaka K, Davie EW, eds. Recent Advances in Thrombosis and Hemostasis. Springer ; 2008 : 597-613.
 
16) Tang L, Guo T, Yang R, et al. Genetic Background Analysis of Protein C Deficiency Demonstrates a Recurrent Mutation Associated with Venous Thrombosis in Chinese Population. PLoS ONE 2012 ; 7 : e35773.
PubMed
17) Tang L, Lu X, Yu JM, et al. PROC c.574_576del polymorphism : a common genetic risk factor for venous thrombosis in the Chinese population. J Thromb Haemost 2012 ; 10 : 2019-2026.
 
18) Tang L, Jian XR, Hamasaki N, et al. Molecular basis of protein S deficiency in China. Am J Hematol 2013 ; 88 : 899-905.
PubMed
19) Chumpia W, Peeraittayamongkol C, Angchaisuksiri P, et al. Single nucleotide polymorphisms and haplotypes of protein C and protein S genes in the Thai population. Blood Coagul Fibrinolysis 2006 ; 17 : 13-18.
PubMed
20) Angchaisuksiri P, Atichartakarn V, Aryurachai K, et al. Risk factors of venous thromboembolism in Thai patients. Int J Hematol 2007 ; 86 : 397-402.
PubMed
21) Kim HJ, Seo JY, Lee KO, et al. Distinct frequencies and mutation spectrums of genetic thrombophilia in Korea in comparison with other Asian countries both in patients with thromboembolism and in the general population. Haematologica 2014 ; 99 : 561-569.
PubMed
22) Roberts LN, Patel K, Arya R. Venous thromboembolism and ethnicity. Br J Haematol 2009 ; 46 : 369-383.
 
23) Kimura R, Honda S, Kawasaki T, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood 2006 ; 107 : 1737-1738.
PubMed
24) Ikejiri M, Wada H, Sakamoto Y, et al. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol 2010 ; 92 : 302-305.
PubMed
25) Schmidel DK, Tatro AV, Phelps LG, et al. Organization of the human protein S genes. Biochemistry 1990 ; 29 : 7845-7852.
PubMed
26) Johansson AM, Hillarp A, Sall T, et al. Large deletions of the PROS1 gene in a large fraction of mutation-negative patients with protein S deficiency. Thromb Haemost 2005 ; 94 : 951-957.
 
27) Yin T, Takeshita S, Sato Y, et al. A large deletion of the PROS1 gene in a deep vein thrombosis patient with protein S deficiency. Thromb Haemost 2007 ; 98 : 783-789.
 
28) Lind-Hallden C, Dahlen A, Hillarp A, et al. Small and large PROS1 deletions but no other types of rearrangements detected in patients with protein S deficiency. Thromb Haemost 2012 ; 108 : 94-100.
PubMed
29) Choung HS, Kim HJ, Gwak GY, et al. Inherited protein S deficiency as a result of a large duplication mutation of the PROS1 gene detected by multiplex ligationdependent probe amplification. J Thromb Haemost 2008 ; 6 : 1430-1432.
PubMed
30) Shigekiyo T, Uno Y, Kawauchi S, et al. Protein S Tokushima : An abnormal protein S found in a Japanese family with thrombosis. Thromb Haemost 1993 ; 70 : 244-246.
 
31) Yamazaki Y, Sugiura I, Matsushita T, et al. A phenotypically neutral dimorphism of protein S : the substitution of Lys155 by Glu in the second EGF domain predicted by an A to G base exchange in the gene. Thromb Res 1993 ; 70 : 395-403.
 
32) Liu W, Yin T, Okuda H, et al.Protein S K196E mutation, a genetic risk factor for venous thromboembolism, is limited to Japanese. Thromb Res 2013 ; 132 : 314-315.
PubMed
33) Heit JA, Petterson TM, Owen WG, et al. Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism : a populationbased case-control study. J Thromb Haemost 2005 ; 3 : 710-717.
PubMed
34) Sugiyama S, Hirota H, Kimura R, et al. Haplotype of thrombomodulin gene associated with plasma thrombomodulin level and deep vein thrombosis in the Japanese population. Thromb Res 2007 ; 119 : 35-43.
PubMed
35) Tang L, Wang HF, Lu X, et al. Common genetic risk factors for venous thrombosis in the Chinese population. Am J Hum Genet 2013 ; 92 : 177-187.
PubMed
36) Dennis J, Johnson CY, Adediran AS, et al. The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders : a HuGE review and meta-analysis of evidence from observational studies. Blood 2012 ; 119 : 2392-2400.
PubMed
37) Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995 ; 346 : 1133-1134.
PubMed
38) Tsuda T, Jin X, Tsuda H, et al. New quantitative total protein S-assay system for diagnosing of protein S type II deficiency : clinical application of the screening system for protein S type II deficiency. Blood Coagul Fibrinolysis 2012 ; 23 : 56-63.
PubMed
39) 濱崎直孝. 新しく開発したプロテインS比活性測定法 (自動分析法) による血栓性素因の判定. 臨床化学 2012 ; 41 : 349-358.
Medical*Online
40) Martinelli I, Bucciarelli P, Mannucci PM. Thrombotic risk factors : basic pathophysiology. Crit Care Med 2010 ; 38 (2 Suppl) : CS3-CS9.
 
41) Tsay W, Shen MC. R147W mutation of PROC gene is common in venous thrombotic patients in Taiwanese Chinese. Am J Hematol 76 : 8-13.
PubMed
P.64 掲載の参考文献
1) CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013 ; 45 : 25-33.
PubMed
2) Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009 : 461 : 747-753.
PubMed
3) McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007 ; 316 : 1488-1491.
PubMed
4) Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007 ; 316 : 1491-1493.
PubMed
5) Wellcome Trust Case Control Consortium. Genomewide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007 ; 447 : 661-678.
 
6) Samani NJ, Erdmann J, Hall AS, et al. Genomewide Association Analysis of Coronary Artery Disease. N Engl J Med 2007 ; 357 : 443-453.
PubMed
7) Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007 ; 316 : 1336-1341.
PubMed
8) Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genomewide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007 ; 316 : 1341-1345.
PubMed
9) Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007 ; 316 : 1331-1336.
PubMed
10) Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008 ; 40 : 217-224.
PubMed
11) Schunkert H, Gotz A, Braund P, et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 2008 ; 117 : 1675-1684.
 
12) Broadbent HM, Peden JF, Lorkowski S, et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet 2008 ; 17 : 806-814.
PubMed
13) Jarinova O, Stewart AF, Roberts R, et al. Functional Analysis of the Chromosome 9p21.3 Coronary Artery Disease Risk Locus. Arterioscler Thromb Vasc Biol 2009 ; 29 : 1671-1677.
PubMed
14) Yamada Y, Nishida T, Ichihara S, et al. Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations. Atherosclerosis 2011 ; 215 : 145-152.
PubMed
15) Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002 ; 32 : 650-654.
 
16) Ozaki K, Inoue K, Sato H, et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro. Nature 2004 ; 429 : 72-75.
 
17) Ozaki K, Sato H, Iida A, et al. A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population. Nat Genet 2006 ; 38 : 921-925.
PubMed
18) Ozaki K, Sato H, Inoue K, et al. SNPs in BRAP associated with risk of myocardial infarction in Asian populations. Nat Genet 2009 ; 41 : 329-333.
PubMed
19) Clarke R, Xu P, Bennett D, et al. Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genet 2006 ; 2 : e107.
 
20) Traylor M, Farrall M, Holliday EG, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration) : a meta-analysis of genome-wide association studies. Lancet Neurol 2012 ; 11 : 951-962.
 
21) Kilarski LL, Achterberg S, Devan WJ, et al. Metaanalysis in more than 17,900 cases of ischemic stroke reveals a novel association at 12q24.12. Neurology 2014 ; 83 : 678-685.
PubMed
22) Ikram MA, Seshadri S, Bis JC, et al. Genomewide association studies of stroke. N Engl J Med 2009 ; 360 : 1718-1728.
PubMed
23) Rosand J, Meschia JF, Singleton AB. Failure to validate association between 12p13 variants and ischemic stroke. N Engl J Med 2010 ; 362 : 1547-1550.
PubMed
24) Gretarsdottir S, Thorleifsson G, Manolescu A, et al. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol 2008 ; 64 : 402-409.
PubMed
25) Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet 2009 ; 41 : 876-878.
PubMed
26) The International Stroke Genetics Consortium (ISGC), the Wellcome Trust Case Control Consortium 2 (WTCCC2) : Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet 2012 ; 44 : 328-333.
 
27) Kubo M, Hata J, Ninomiya T, et al. A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat Genet 2007 ; 39 : 212-217.
PubMed
28) Hata J, Matsuda K, Ninomiya T, et al. Functional SNP in an Sp1-binding site of AGTRL1 gene is associated with susceptibility to brain infarction. Hum Mol Genet 2007 ; 16 : 630-639.
 
29) Yamada Y, Fuku N, Tanaka M, et al. Identification of CELSR1 as a susceptibility gene for ischemic stroke in Japanese individuals by a genome-wide association study. Atherosclerosis 2009 ; 207 : 144-149.
PubMed
30) Gouveia LO, Sobral J, Vicente AM, et al. Replication of the CELSR1 association with ischemic stroke in a Portuguese case-control cohort. Atherosclerosis 2011 ; 217 : 260-262.
 
P.79 掲載の参考文献
1) Van de Wouwer M, et al. Thrombomodulin-protein C-EPCR system : integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004 ; 24 : 1374-1383.
PubMed
2) Minami T, et al. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 2004 ; 24 : 41-53.
PubMed
3) Minami T, Aird WC. Thrombin stimulation of the vascular cell adhesion molecule-1 promoter in endothelial cells is mediated by tandem nuclear factor-kappa B and GATA motifs. J Biol Chem 2001 ; 276 : 47632-4 7641.
 
4) Kaplanski G, et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1 ; CD54) and vascular cell adhesion molecule-1 (VCAM-1 ; CD106). Blood 1998 ; 92 : 1259-1267.
PubMed
5) Kaplanski G, et al. Thrombin induces endothelial type II activation in vitro : IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. J Immunol 1997 ; 158 : 5435-5441.
 
6) Eto M, et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways : role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001 ; 89 : 583-590.
PubMed
7) Minami T, et al. The Down syndrome critical region gene 1 short variant promoters direct vascular bedspecific gene expression during inflammation in mice. The Journal of clinical investigation 2009 ; 119 : 2257-2270.
PubMed
8) Minami T, et al. Vascular endothelial growth factorand thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J Biol Chem 2004 ; 279 : 50537-50554.
 
9) Wu SQ, et al. The proximal serum response element in the Egr-1 promoter mediates response to thrombin in primary human endothelial cells. Blood 2002 ; 100 : 4454-4461.
PubMed
10) Suehiro J, et al. Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3. Blood 2010 ; 115 : 2520-2532.
PubMed
11) Lidington EA, et al. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complementmediated injury. Blood 2000 ; 96 : 2784-2792.
PubMed
12) Yin Z, et al. The essential role of Cited2, a negative regulator for HIF-1alpha, in heart development and neurulation. Proc Natl Acad Sci U S A 2002 ; 99 : 10488-10493.
PubMed
13) Luque A, et al. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 2003 ; 278 : 23656-23665 .
PubMed
14) Goda S, et al. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and-independent mechanisms. J Immunol 2000 ; 164 : 4313-4320.
PubMed
15) Stiehl T, et al. Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis. Critical care medicine 2014 ; 42 : e654-e662.
PubMed
16) Ziegler T, et al. Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest. 2013 ; 123(8) : 3436-3445.
PubMed
17) Minami, T. Calcineurin-NFAT activation and DSCR-1 auto-inhibitory loop : how is homoeostasis regulated? Journal of biochemistry 2014 ; 155 : 217-226.
 
18) Minami T, et al. Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium. J Biol Chem 2006 ; 281 : 20503-20520.
PubMed
19) Shin JW, et al. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood 2008 ; 112 : 2318-2326.
PubMed
20) Kothapalli R, et al. Microarray results : how accurate are they? BMC Bioinformatics 2002 ; 3, 22.
PubMed
21) de Reynies A, et al. Comparison of the latest commercial short and long oligonucleotide microarray technologies. BMC Genomics 2006 ; 7 : 51.
 
22) Zhuang G, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012 ; 31 : 3513-3523.
PubMed
23) Vasilescu C, et al. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PloS one 2009 ; 4 : e 7405 .
 
24) Raitoharju E. MicroRNA-616 and atherosclerosis--a commentary on the paper by Liu et al. Atherosclerosis 2013 ; 228 : 42-43.
 
25) Kanki Y, et al. Epigenetically coordinated GATA2 binding is necessary for endothelium-specific endomucin expression. The EMBO journal 2011 ; 30 : 2582-2595.
PubMed
26) Tozawa H, et al. Genome-wide approaches reveal functional interleukin-4-inducible STAT6 binding to the vascular cell adhesion molecule 1 promoter. Mol Cell Biol 2011 ; 31 : 2196-2209.
 
27) Suehiro J, et al. Genome-wide Approaches Reveal Functional Vascular Endothelial Growth Factor (VEGF)-inducible Nuclear Factor of Activated T Cells (NFAT) c1 Binding to Angiogenesis-related Genes in the Endothelium. J Biol Chem 2014 ; 28 : 29044-29059.
 
28) Ozawa Y, et al. Histone deacetylase 3 associates with and represses the transcription factor GATA-2. Blood 2001 ; 98 : 2116-2123.
PubMed
29) Yu M, et al. Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. Mol Cell 2009 ; 36 : 68 2-695.
 
30) Kumbrink J, Kirsch KH, Johnson JP. EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin. Journal of cellular biochemistry 2010 ; 111 : 207-217.
PubMed
31) Inoue K, et al. Histone deacetylase inhibitor reduces monocyte adhesion to endothelium through the suppression of vascular cell adhesion molecule-1 expression. Arterioscler Thromb Vasc Biol 2006 ; 26 : 2652-2659.
PubMed
32) Bavendiek U, et al. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 2002 ; 277 : 25032-25039.
PubMed
33) Riewald M, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002 ; 296 : 1880-1882.
PubMed
P.88 掲載の参考文献
1) Cooley BC, Chen CY, Schmeling G. Increased venous versus arterial thrombosis in the Factor V Leiden mouse. Thromb Res 2007 ; 119 : 747-751.
PubMed
2) Kashiwakura Y, Mimuro J, Onishi A, et al. Porcine model of hemophilia A. PLoS One 2012 ; 7 : e49450.
PubMed
3) Chan JC, Ganopolsky JG, Cornelissen I, et al. The characterization of mice with a targeted combined deficiency of protein c and factor XI. Am J Pathol 2001 ; 158 : 469-479.
PubMed
4) Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005 ; 202 : 271-281.
PubMed
5) Koseki-Kuno S, Yamakawa M, Dickneite G, et al. Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages. Blood 2003 ; 102 : 4410-4412.
PubMed
6) Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000 ; 106 : 873-878.
PubMed
7) Yanada M, Kojima T, Ishiguro K, et al. Impact of antithrombin deficiency in thrombogenesis : lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 2002 ; 99 : 2455-2458.
PubMed
8) Gu JM, Crawley JT, Ferrell G, et al. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem 2002 ; 277 : 43335-43343.
PubMed
9) Isermann B, Hendrickson SB, Zogg M, et al. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest 2001 ; 108 : 537-546.
PubMed
10) White TA, Johnson T, Zarzhevsky N, et al. Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis. Blood 2010 ; 116 : 1787-1794.
PubMed
11) Lijnen HR. Gene targeting in hemostasis. Alpha2-antiplasmin. Front Biosci 2001 ; 6 : D239-D247.
PubMed
12) Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994 ; 368 : 419-424.
PubMed
13) Dewerchin M, Nuffelen AV, Wallays G, et al. Generation and characterization of urokinase receptordeficient mice. J Clin Invest 1996 ; 97 : 870-878.
PubMed
14) Gurney AL, Carver-Moore K, de Sauvage FJ, et al. Thrombocytopenia in c-mpl-deficient mice. Science 1994 ; 265 : 1445-1447.
 
15) de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996 ; 183 : 651-656.
PubMed
16) Banno F, Kokame K, Okuda T, et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006 ; 107 : 3161-3166.
 
17) Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction : the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A 2000 ; 97 : 2803-2808.
PubMed
18) Strassel C, Nonne C, Eckly A, et al. Decreased thrombotic tendency in mouse models of the Bernard-Soulier syndrome. Arterioscler Thromb Vasc Biol 2007 ; 27 : 241-247.
PubMed
19) Tronik-Le Roux D, Roullot V, Poujol C, et al. Thrombasthenic mice generated by replacement of the integrin alpha(IIb) gene : demonstration that transcriptional activation of this megakaryocytic locus precedes lineage commitment. Blood 2000 ; 96 : 1399-1408.
PubMed
20) Ghosh A, Li W, Febbraio M, et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest 2008 ; 118 : 1934-1943.
PubMed
21) Ni H, Ramakrishnan V, Ruggeri ZM, et al. Increased thrombogenesis and embolus formation in mice lacking glycoprotein V. Blood 2001 ; 98 : 368-373.
PubMed
22) Kato K, Kanaji T, Russell S, et al. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 2003 ; 102 : 1701-1707.
PubMed
23) Leon C, Hechler B, Freund M, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 1999 ; 104 : 1731-1737.
PubMed
24) Andre P, Delaney SM, LaRocca T, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003 ; 112 : 398-406.
PubMed
25) Damiano BP, Cheung WM, Santulli RJ, et al. Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther 1999 ; 288 : 671-678.
PubMed
26) Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998 ; 394 : 690-694.
 
27) Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2004 ; 2 : 1429-1435.
PubMed
28) Hankenson KD, Hormuzdi SG, Meganck JA, et al. Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have accelerated development of the femoral head. Mol Cell Biol 2005 ; 25 : 5599-5606.
PubMed
29) Frolova EG, Pluskota E, Krukovets I, et al. Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circ Res 2010 ; 107 : 1313-1325.
PubMed
30) Reheman A, Yang H, Zhu G, et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 2009 ; 113 : 1809-1817.
 
31) Nagy A. Cre recombinase : the universal reagent for genome tailoring. Genesis 2000 ; 26 : 99-109.
PubMed
32) Kleinhammer A, Wurst W, Kuhn R. Gene knockdown in the mouse through RNAi. Methods Enzymol 2010 ; 477 : 387-414.
PubMed
33) Shen B, Zhang J, Wu H, et al. Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res 2013 ; 23 : 720-723.
 
34) Niu Y, Shen B, Cui Y, et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 2014 ; 156 : 836-843.
PubMed
35) Iwaki T, Nagahashi K, Kobayashi T, et al. The first report of uncontrollable subchorionic and retroplacental haemorrhage inducing preterm labour in complete PAI-1 deficiency in a human. Thromb Res 2012 ; 129 : e161-e163.
 
36) Gladson CL, Groncy P, Griffin JH. Coumarin necrosis, neonatal purpura fulminans, and protein C deficiency. Arch Dermatol 1987 ; 123 : 1701a-1706a.
PubMed
37) Gomez E, Ledford MR, Pegelow CH, et al. Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene. Thromb Haemost 1994 ; 71 : 723-726.
PubMed
38) Cleuren AC, Van Oerle R, Reitsma PH, et al. Longterm estrogen treatment of mice with a prothrombotic phenotype induces sustained increases in thrombin generation without affecting tissue fibrin deposition. J Thromb Haemost 2012 ; 10 : 2392-2394.
PubMed
39) Tchaikovski SN, van Vlijmen BJ, Cleuren AC, et al. Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice. J Thromb Haemost 2009 ; 7 : 312-318.
PubMed
40) Nagai N, Lijnen HR, Cleuren AC, et al. Factor V Leiden mutation is associated with enhanced arterial thrombotic tendency in lean but not in obese mice. Thromb Haemost 2007 ; 98 : 858-863.
 
41) van Helden PM, Unterthurner S, Hermann C, et al. Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model. Blood 2011 ; 118 : 3698-3707.
 

2部 出血病と血栓症の治療

P.100 掲載の参考文献
1) 朝倉英策. 止血の生理と血栓の病態. In : 朝倉英策編. 臨床に直結する血栓止血学. 東京 : 中外医学社 2013 : 2-11.
 
2) 森下英理子. 先天性アンチトロンビン・プロテインC・プロテインS欠損症. In : 朝倉英策編. 臨床に直結する血栓止血学. 東京 : 中外医学社 2013 : 268-274.
 
3) 山田典一. 深部静脈血栓症・肺血栓塞栓症. In : 朝倉英策編. 臨床に直結する血栓止血学. 東京 : 中外医学社 2013 : 287-292.
 
4) 山崎昌子. 抗血小板療法. In : 朝倉英策編. 臨床に直結する血栓止血学, p312-316, 中外医学社, 2013 : 312-316.
 
5) 小嶋哲人 : ワルファリン. In : 朝倉英策編. 臨床に直結する血栓止血学. 東京 : 中外医学社, 2013 : 317-320.
 
6) 朝倉英策. 新規経口抗凝固薬. In : 朝倉英策編. 臨床に直結する血栓止血学. 東京 : 中外医学社, 2013 : 321-329.
 
7) 浦野哲盟 : 線溶療法. In : 朝倉英策編. 臨床に直結する血栓止血学. 東京 : 中外医学社, 2013 : 337-341.
 
8) 朝倉英策 : 播種性血管内凝固症候群 (DIC). In : 朝倉英策著. しみじみわかる血栓止血. 東京 : 中外医学社, 2014 : 48-141.
 
9) Ontachi Y, Asakura H, Arahata M, et al. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm. Circ J 2005 ; 69 : 1150-1153.
PubMed
10) Ontachi Y, Asakura H, Omote M, et al. Kasabach-Merritt syndrome associated with giant liver hemangioma : the effect of combined therapy with danaparoid sodium and tranexamic acid. Haematologica 2005 ; 90(Suppl) : ECR29.
 
11) Hayashi T, Nakagawa N, Asakura H, et al. Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm : a case report. Ann Intern Med 2014 ; 161 : 158-159.
 
12) Gaillard S, Dupuis-Girod S, Boutitie F, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients : a European cross-over controlled trial in a rare disease. J Thromb Haemost 2014 ; 12 : 1494-1502.
 
13) Geisthoff UW, Seyfert UT, Kubler M, et al. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid-a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res 2014 ; 134 : 565-571.
PubMed
14) 塩谷隆信. 遺伝性出血性末梢血管拡張症 (オスラー病). In : 朝倉英策編. 臨床に直結する血栓止血学. 東京 : 中外医学社, 2013 : 152-160.
 
P.107 掲載の参考文献
1) Quinlan GJ, Martin GS, Evans TW. Albumin : biochemical properties and therapeutic potential. Hepatology 2005 ; 41 : 1211-1219.
PubMed
2) Garcia-Martinez R, Caraceni P, Bernardi M, et al. Albumin : pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013 ; 58 : 1836-1846.
PubMed
3) 厚生労働省医薬品食品局血液対策課 : 血液製剤の使用指針. 改訂版. 薬食発第0306第4号. 2012年3月6日.
 
4) Kim SB, Chi HS, Park JS et al. Effect of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation in CAPD patients. Am J Kidney Dis 1999 ; 33 : 312-317.
PubMed
5) 桑名正隆. ITPの診断と治療. 血栓止血誌 2008 ; 19 : 199-201.
 
6) Nilsson IM, Berntorp E. Freiburghaus C. Treatment of patients with FVIII and IX inhibitors. Thromb Haemost 1993 ; 70 : 56-59.
 
7) Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors : a systematic review. Haemophilia 2003 ; 9 : 436-463.
PubMed
8) Stiefel M1, Pinkwart C, Haase R, et al. Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin. Hamostaseologie 2010 ; 30 suppl 1 : S119-S121.
 
9) Richards M, Williams M, Chalmers E, et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology : guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010 ; 149 : 498-507.
 
10) 藤井輝久, 天野景裕, 渥美達也, 他. インヒビターのない血友病患者に対する止血治療ガイドライン : 2013年改訂版. 血栓止血誌 2013 ; 24 : 619-639.
 
11) 酒井道生, 瀧正志, 家子正裕, 他. インヒビター保有先天性血友病患者に対する止血治療ガイドライン : 2013年改訂版. 血栓止血誌 2013 ; 24 : 640-658.
 
12) 鈴木隆史. 血液凝固因子製剤 (vWF, fibrinogen, factor XIII) . 血栓止血誌 2009 ; 20 : 3-5.
 
13) 高松純樹. 先天性フィブノリノゲン欠乏症/異常フィブリノゲン血症. 日本臨床 1998 ; 21 : 449-455.
 
14) Yamamoto K, Usui A, Takamatsu J. Fibrinogen concentrate administration attributes to significant reductions of blood loss and transfusion requirements in thoracic aneurysm repair. J Cardiothorac Surg 2014 ; 19 : 90.
 
15) 福江英尚, 新井盛夫. 第XI因子Aサブユニット欠損症. 血栓止血誌 2001 ; 912 : 66-73.
 
16) 熊井浩一郎. 第XIII因子製剤-外科 : 性状と作用機序-臨床. Biomedical Perspectives 1999 ; 8 : 38-44.
 
17) 白幡聡. 第XIII因子製剤-小児科 : Schonlein-Henoch紫斑病. Biomedical Perspectives 1999 ; 8 : 45-52.
 
18) Ichinose A. Inhibitors of Factor XIII/13 in older patients. Semin Thromb Hemost 2014 ; 40 : 704-711.
PubMed
19) 一瀬白帝. 後天性血友病XIII (13) (出血性後天性凝固第13因子欠乏症) とは? 日内会誌 2010 ; 99 : 1934-1943.
 
20) 辻肇. 先天性アンチトロンビンI (ATI) 欠損症. 血栓止血誌 2001 ; 12 : 74-77.
 
21) 丸山征郎, 坂田洋一, 和田英夫, 他. 科学的根拠に基づいた感染症に伴うDIC治療におけるエキスパートコンセンサス. 血栓止血誌 2009 ; 20 : 77-113.
 
22) 山本晃士. プロテインC (PC) 欠乏症. 血栓止血誌 2001 ; 12 : 149-153.
 
23) Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the new born. N Engl J Med 1984 ; 310 : 559-562.
 
24) Schaer DJ, Vinchi F, Ingoglia G. Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development. Front Physiol 2014 ; 28 : 415.
 
25) 安村敏. 血漿分画製剤 : 血漿蛋白の役割. In : 大阪顯通編. 輸血学テキスト. 東京 : 中外医学社. 2013 ; 104-114.
 
P.113 掲載の参考文献
1) 高松純樹. 緊急輸血の大原則. In : 山本晃士編, 図解臨床輸血ガイド. 東京 : 文光堂, 2011 : 2-18.
 
2) Wallis JP, Dzik S. Is fresh frozen plasma overtransfused in the United States? Transfusion 2004 ; 44 : 1674-1675.
PubMed
3) Rossaint R, Bouillon B, Cerny V, et al. Management of bleeding following major trauma : an updated European guideline. Crit Care 2010 ; 14 : R52.
PubMed
4) Tripodi A, Caldwell SH, Hoffman M, et al. The prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007 ; 26 : 141-148.
PubMed
5) Segal JB, Dizk WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures : an evidence-based review. Transfusion 2005 ; 45 : 1413-1425.
 
6) Chowdhury P, Saayman AG, Paulus U, et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004 ; 125 : 69-73.
 
7) Appadu BL. Prolongation of prothrombin time in the critically ill : Is it time for decisive action? Crit Care Med 2010 ; 38 : 2065-2066.
PubMed
8) Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma poor red cell concentrates. Anesth Analg 1995 ; 81 : 360-365.
PubMed
9) 山本晃士. 新鮮凍結血漿の投与基準を検証する-実効性のあるトリガー値の提唱-. 日本輸血細胞治療学会誌 2011 ; 57 : 442-448.
Medical*Online
10) 山本晃士, 西脇公俊, 加藤千秋, 他. 術中大量出血を防ぐための新たな輸血治療-クリオプレシピテートおよびフィブリノゲン濃縮製剤投与効果の検討-. 日本輸血細胞治療学会誌 2010 ; 56 : 36-42.
Medical*Online
11) 山本晃士. 術中大量出血時の輸血療法. In : 山本晃士編, 図解臨床輸血ガイド. 東京 : 文光堂, 2011 ; 118-132.
 
12) 小林隆夫. 産科領域の大量出血と輸血療法. 医学のあゆみ「周術期輸血医療UPDATE」 224 : 221-226, 2008.
 
13) 板倉敦夫. 産科領域の輸血療法. In : 山本晃士編, 図解臨床輸血ガイド. 東京 : 文光堂, 2011 : 105-117.
 
14) 安村敏. FFP 輸血の適応と注意点. In : 山本晃士編, 図解臨床輸血ガイド. 東京 : 文光堂, 2011 : 28-43.
 
15) Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004 ; 126 : 139-152.
PubMed
16) Dara SI, Rana R, Afessa B, et al. Fresh frozen plasma transfusion in critically ill medical patients with coagulopathy. Crit Care Med 2005 ; 33 : 2667-2671.
PubMed
17) Scalea TM, Bochicchio KM, Lumpkins K, et al. Early aggressive use of fresh frozen plasma does not improve outcome in critically injured trauma patients. Ann Surg 2008 ; 248 : 578-584.
 
18) Tripodi A, Chantarangkul V, Primignani M. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma : considerations on the efficacy of treatment with fresh-frozen plasma. Intern Emerg Med 2012 ; 7 : 139-144.
PubMed
19) Lisman T, Bakhtiari K, Pereboom IT, et al. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol 2010 ; 52 : 355-361.
PubMed
20) Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease : Pathophysiology and critical assessment of current management. Hepatology 2006 ; 44 : 1039-1046.
PubMed
21) Tripodi A, Primignani M, Mannucci PM. Abnormalities of hemostasis and bleeding in chronic liver disease : the paradigm is challenged. Intern Emerg Med 2010 ; 5 : 7-12.
PubMed
22) Casbard AC, Williamson LM, Murphy MF, et al. The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. Anaesthesia 2004 ; 59 : 550-558.
PubMed
23) Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008 ; 101 : 769-773.
PubMed
24) O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004 ; 126 : 11-28.
PubMed
25) Practice guidelines for perioperative blood transfusion and adjuvant therapy. An update report by the American Society for Anesthesiologists Task Force on perioperative blood transfusion and adjuvant therapy. Anesthesiology 2006 ; 105 : 198-208.
PubMed
26) Danes AF, Cuenca LG, Bueno SR, et al. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 2008 ; 94 : 221-226.
PubMed
27) Sorensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010 ; 149 : 834-843.
 
28) Rahe-Meyer N, Sorensen B. Fibrinogen concentrate for management of bleeding. J Thromb Haemost 2011 ; 9 : 1-5.
PubMed
29) 羽藤高明. 血小板輸血の現状と将来. 日本血栓止血学会誌 2005 ; 16 : 273-280.
 
30) 渡邊直英, 半田誠. 血小板輸血の適応と実際. In : 山本晃士編, 図解臨床輸血ガイド. 東京 : 文光堂, 2011 : 44-57.
 
P.120 掲載の参考文献
1) 山下武志. 心が動けば医療も動く!? メディカル・サイエンス・インターナショナル社, 2009.
 
2) 山下武志. New and New心房細動の抗凝固療法. メディカル・サイエンス・インターナショナル社, 2014.
 
3) Umer Usman MH, Raza S, Ezekowits M, et al. Advancement in antithrombotics for stroke prevention in atrial fibrillation. J Interv Card Electrophysiol 2008 ; 22 : 129-137.
 
4) Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005 ; 353 : 1028-1040.
PubMed
5) DeWald TA, Becker RC. The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis 2014 ; 37 : 217-233.
PubMed
6) Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet 2014 ; 383 : 955-962.
PubMed
7) Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013 ; 369 : 1206-1214.
PubMed
P.129 掲載の参考文献
1) 日本循環器学会合同研究班報告. 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf
 
2) Camm AJ, et al. Guidelines for the management of atrial fibrillation : The task force for the management of atrial fibrillation of the ESC. Eur Heart J. 2010 ; 31 : 2369-2429.
PubMed
3) Camm AJ, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace. 2012 ; 14 : 1385-1413.
PubMed
4) January CT, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014 ; 130 : 2071-2104.
 
5) Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol 2014 ; 30 : 1114-1130.
PubMed
6) Tomita H, et al. Validation of risk scoring system excluding female sex from CHA2DS2-VASc in japanese patients with nonvalvular atrial fibrillation-Subanalysis of the J-RHYTHM Registry-. Circ J 2015 ; 79 : 1719-1726.
 
7) 日本循環器学会合同研究班報告. カテーテルアブレーションの適応と手技に関するガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2012_okumura_h.pdf
 
8) Singer DE, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009 ; 151 : 297-305.
PubMed
9) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 ; 361 : 1139-1151.
PubMed
10) Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 ; 365 : 883-891.
PubMed
11) Hori Ml, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation. The J-ROCKET AF study. Circ J. 2012 ; 76 : 2104-2111.
 
12) Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 ; 365 : 981-992.
PubMed
13) Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 ; 369 : 2093-2104.
PubMed
14) Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients : the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014 ; 63 : 321-328.
 
15) Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet 2014 ; 383 : 955-962.
PubMed
16) Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial. Eur Heart J 2012 ; 33 : 2821-2830.
PubMed
P.138 掲載の参考文献
1) 肺血栓塞栓症および深部静脈血栓症の診断・治療・予防に関するガイドライン (2009年改訂版) : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf
 
2) Nakamura M, Okano Y, Minamiguchi H, et al. Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Circ J 2011 ; 75 : 1424-1432.
PubMed
3) Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty : the STARS E-3 trial. Thromb Res 2014 ; 134(6) : 1198-1204.
PubMed
4) Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty 2014 ; 29(12) : 2439-2446.
PubMed
5) Fuji T, Fujita S, Kawai Y, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res. 2014 ; 133(6) : 1016-1022.
PubMed
6) Hokusai-VTE Investigators, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013 ; 369(15) : 1406-1415.
PubMed
7) Nakamura M, Yamada N, Ito M. Current management of venous thromboembolism in Japan : Current epidemiology and advances in anticoagulant therapy. J Cardiol 2015 ; doi : 10.1016/j.jjcc.2015.03.012.
 
8) Konstantinides SV, Torbicki A, Agnelli G, et al. ; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014 ; 35(43) : 3033-3069
 
P.146 掲載の参考文献
1) Barnes GD, Ageno W, Ansell S, et al. Recommendation on the nomenclature for oral anticoagulants : communication from the SSC of the ISTH. J Thronb Haemost 2015 ; 13(6) : 1154-1156.
 
2) 北島勲 : 新規経口抗凝固薬のチェック検査. 血液フロンテイア. 2012 ; 22(7) : 45-52.
 
3) 北島勲 : 新規抗凝固薬のモニタリング. In : 豊田一則編. 心原性脳梗塞と経口抗凝固薬. 大阪 : フジメデイカル出版, 2013 ; 88-99.
 
4) 北島勲 : 新規経口抗凝固薬の薬理学的特徴. 循環器内科 2014 ; 75(5) : 542-548.
 
5) Eisert WG, Hauel N, Stangier J, et al. Dabigatran : An oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Veas Biol 2010 ; 30 : 1885-1889.
 
6) Adcock DM, Gosselin R, Kitchen S, et al. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol. 2013 ; 139 : 102-109.
PubMed
7) Dager WE, Gosselin RC, Kitchen S, et al. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen : a multicenter, in vitro study. Ann Pharmacother 2012 ; 46(12) : 1627-1636.
PubMed
8) van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate. a novel reversible, oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010 ; 103(6) : 1116-1127.
PubMed
9) Butenas S, Mann KG. Kinetics of human Factor VII activation. Biochemistry 1996 ; 35 : 1904-1910.
PubMed
10) Mani H, Hesse C, Stratmann G, et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013 ; 109 : 127-136.
PubMed
11) Samama MM, Nartinoli J-L, Le-Flem L, et al. Assessment of laboratory assays to measure rivaroxaban : an oral, direct factor Xa inhibitor. Throbosis and Haemostasis 2010 ; 103 : 815-825.
 
12) Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012 ; 23 : 138-143.
PubMed
13) Douxfils J, Mullier F, Robert S. et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012 ; 107 : 985-997.
PubMed
14) Schmitz EM, Boonen K, van den Heuvel DJ, et al. Determination of dabigatran, rivaroxaban and apixaban by UPLC-MS/MS and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014 ; 12 : 1636-1646.
 
15) Jackson II LR, Becker RC. Novel oral anticoagulants : pharmacology, coagulation measures, and considerations for reversal. J Thromb Thrombolysis 2014 ; 37 : 380-391.
 
16) Dinkelaar J, Patiwael S, Harenberg J, et al. Global coagulation tests : their applicability for measuring direct factor Xa-and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med 2014 ; 52 : 1615-1623.
PubMed
P.154 掲載の参考文献
1) Takii T, Yasuda S, Takahashi J, et al. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan : report from the MIYAGI-AMI Registry Study. Circ J 2010 ; 74(1) : 93-100.
PubMed
2) 佐藤直樹, 吉田伸子, 高山守正. 東京都CCUネットワーク活動状況報告. ICUとCCU. 2011 ; 35 : 827-829.
Medical*Online
3) Ui S, Chino M, Isshiki T. Rates of primary percutaneous coronary intervention worldwide. Circ J 2005 ; 69(1) : 95-100.
PubMed
4) Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction : a randomised study. Lancet. 2002 ; 360(9336) : 825-829.
PubMed
5) Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial? PRAGUE-2. Eur Heart J 2003 ; 24(1) : 94-104.
PubMed
6) Ogawa H, Kojima S. Modern state of acute myocardial infarction in the interventional era : observational casecontrol study : Japanese acute coronary syndrome study (JACSS). J Cardiol 2009 ; 54(1) : 1-9.
PubMed
7) Rentrop KP, Blanke H, Karsch KR, et al. Acute myocardial infarction : intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979 ; 2(5) : 354-363.
PubMed
8) 梶原長雄, 上松瀬勝男, 八木洋, 他. 急性心筋梗塞の臨床ウロキナーゼ. 診断と治療. 1981 ; 69(3) : 420-428.
 
9) 木村一雄. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). ST 上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版). 2013.
 
10) Kumasaka N, Sakuma M, Shirato K. Incidence of pulmonary thromboembolism in Japan. Japanese circulation journal. 1999 ; 63(6) : 439-441.
PubMed
11) Sakuma M, Nakamura M, Yamada N, et al. Venous thromboembolism : deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J 2009 ; 73(2) : 305-309.
PubMed
12) Sakuma M, Okada O, Nakamura M, et al. Recent developments in diagnostic imaging techniques and management for acute pulmonary embolism : multicenter registry by the Japanese Society of Pulmonary Embolism Research. Intern Med 2003 ; 42(6) : 470-476.
PubMed
13) Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Eng J Med 2014 ; 370(15) : 1402-1411.
 
14) Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of allcause mortality, major bleeding, and intracranial hemorrhage : a meta-analysis. Jama. 2014 ; 311(23) : 2414-2421.
PubMed
15) Chen H, Ren C, Chen H. Thrombolysis versus anticoagulation for the initial treatment of moderate pulmonary embolism : a meta-analysis of randomized controlled trials. Respiratory care. 2014 ; 59(12) : 1880-1887.
 
16) 杉本恒明, 白土邦男, 栗山喬之, 他. 急性肺塞栓症に対するE6010(t-PA 誘導体) の臨床的有用性に関する検討 : プラセボを対照とした多施設二重盲検比較試験. 薬理と治療. 2005 ; 33(7) : 653-683.
Medical*Online
17) 久佐茂樹, 尾林徹, 川崎まり子, 他. 急性肺血栓塞栓症 (aPE) に対するMonteplase 投与の効果ならびに合併症についての検討. Ther Res 2007 ; 28(6) : 1000-1002.
Medical*Online
18) 循環器病の診断と治療に関するガイドライン(2008年度合同研究班報告). 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン(2009年改訂版). 日心外会誌. 2014 ; 43(4) : 1-21.
 
19) Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992 ; 42(5) : 976-982.
 
20) Yamaguchi T, Hayakawa T, Kikuchi H. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis. 1993 ; 3 : 269-272.
 
21) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Eng J Med 1995 ; 333(24) : 1581-1587.
 
22) Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset : Japan Alteplase Clinical Trial (J-ACT). Stroke 2006 ; 37(7) : 1810-1815.
 
23) Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke : an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010 ; 375(9727) : 1695-1703.
PubMed
24) Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke : a meta-analysis of individual patient data from randomised trials. Lancet. 2014 ; 384(9958) : 1929-1935.
PubMed
25) 日本脳卒中学会 脳卒中医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針改訂部会, rt-PA (アルテプラーゼ) 静注療法 適正治療指針 第二版. 脳卒中. 2012 ; 34(6) : 443-80.
Medical*Online
26) Toyoda K, Koga M, Naganuma M, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients : general outcomes and prognostic factors from the SAMURAI register. Stroke 2009 ; 40(11) : 3591-3595.
PubMed
27) Nakagawara J, Minematsu K, Okada Y, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice : the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010 ; 41(9) : 1984-1989.
 
28) Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Eng J Med 2004 ; 351(21) : 2170-2178.
 
29) 古幡博. 【治療可能時間の延長に挑む】 超音波併用血栓溶解療法の原理と未来. 脳と循環. 2012 ; 17(2) : 141-145.
 
30) Koga M, Toyoda K, Kimura K, et al. THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0.6 mg/kg (THAWS) Trial. Int J Stroke 2014 ; 9(8) : 1117-1124.
 
31) Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. New Eng J Medicine. 2012 ; 366(12) : 1099-1107.
 
32) von Kummer R, Albers GW, Mori E, et al. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program. Int J Stroke 2012 ; 7(7) : 589-596.
PubMed
P.162 掲載の参考文献
1) 脳卒中学会脳卒中ガイドライン委員会編. 脳卒中治療ガイドライン 2015. 東京 : 協和企画, 2015 ; 101-112.
 
2) 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版) . 日本循環器学会ホームページ http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf
 
3) 山崎昌子, 内山真一郎. 脳梗塞・一過性脳虚血発作の治療. 再発予防のための抗血小板薬. 辻省次 (総編集), 鈴木則宏 (専門編集). 脳血管障害の治療最前線 <アクチュアル脳・神経疾患の臨床>. 東京. 中山書店, 2014 ; 234-239.
 
4) 内山真一郎. 内科治療の変遷と展望. 日本臨床 2014 ; 72 増刊5 : 13-19.
 
5) Wang Y, Wang Y, Zhao S, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013 ; 369 : 11-19.
PubMed
6) Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 ; 33 : 1849-1860.
 
7) CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 ; 348 : 1329-39.
 
8) Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009 ; 360 : 354-362.
PubMed
9) Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised noninferiority trial. Lancet Neurol 2010 ; 9 : 959-968.
PubMed
10) Uchiyama S, Shinohara Y, Katayama Y, et al. Benefit of cilostazol in patients with high risk of bleeding : subanalysis of cilostazol stroke prevention study 2. Cerebrivasc Dis 2014 ; 37 : 296-303.
PubMed
11) Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) : randomized, doubleblind, placebo-controlled trial. Lancet 2004 ; 364 : 331-337.
PubMed
12) Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Engl J Med 2006 ; 354 : 1706-1717.
PubMed
13) The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012 ; 367 : 817-825.
PubMed
14) Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke 2008 ; 39 : 1740-1745.
PubMed
15) Uchiyama S, Sakai N, Toi S, et al. Final results of cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS). Cerebrovasc Dis Extra 2015 ; 5 : 1-13.
PubMed
16) Toyoda K, Uchiyama S, Hoshino H, et al. Protocol for cilostazol stroke prevention study for antiplatelet combination (CSPS.com) : a randomized, open-label, parallelgroup trail. Int J Stroke 2015 ; 10 : 253-258.
 
17) Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidgorel in patients with acute coronary syndromes. N Engl J Med 2007 ; 357 : 2001-2015.
PubMed
18) Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome : the PRASFIT-ACS study. Circ J 2014 ; 78 : 1684-1692.
PubMed
19) Wallentin L, Becker RC, Buda A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 ; 361 : 1045-1057.
 
20) Toyoda K, Yasaka M, Uchiyama S, et al. Blood pressure levels and bleeding events during antithrombotic therapy : the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke 2010 ; 41 : 1440-1444.
PubMed
21) The SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke : the SPS3 randomised trial. Lancet 2013 ; 382 : 507-515.
 
22) Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy. Stroke 2005 ; 36 : 1588-1593.
PubMed
23) Miyata S, Kada A, Nagatsuka K, et al. Clinical impact of aspirin 'resistance' on the secondary prevention of atherothrombosis. J Thromb Haemost 2011 ; 9(Suppl 2) : 257,
 
24) Price MJ, Berqer PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. JAMA 2011 ; 305 : 1097-1105.
 
25) Gurbel PA, Erlinge D, Ohman EM, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization : the TRILOGY ACS platelet function substudy. JAMA 2012 ; 308 : 1785-1794.
PubMed
26) Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001 ; 345 : 1444-1451.
PubMed
27) Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005 ; 352 : 1305-1316.
PubMed
28) Hart RG, Diener HC, Cautts SB, et al. Embolic strokes of undetermined source : the case for new clinical construct. Lancet Neurol 2014 ; 13 : 429-438.
 
P.168 掲載の参考文献
1) 浦野哲盟, 後藤信哉. 血栓形成と凝固・線溶 : 治療に生かせる基礎医学. 東京 : メディカルサイエンスインターナショナル ; 2013.
 
2) 後藤信哉, 浅田祐士郎. 血栓症 : やさしく, くわしく, わかりやすく. 東京 : 南江堂 ; 2006.
 
3) 鈴木重統, 後藤信哉, 松野一彦. 止血, 血栓ハンドブック. 東京 : 西村書店 ; 2015.
 
4) 後藤信哉編. 抗血栓療法ハンドブック. 東京 : 中外医学社, 2011.
 
5) Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 2001 ; 345 : 494-502.
 
6) 後藤信哉. 循環器領域における血栓症と抗血栓療法. 東京 : メジカルセンス ; 2002.
 
7) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction : Isis-2. Isis-2 (second international study of infarct survival) collaborative group. Lancet 1988 ; 2(8607) : 349-360.
 
8) Collaborative overview of randomised trials of antiplatelet therapy--i : Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet trialists' collaboration. BMJ 1994 ; 308 : 81-106.
PubMed
9) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 ; 324 : 71-86.
PubMed
10) Antithrombotic Trialists' (ATT) Collaboration ; Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease : Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 ; 373 (9678) : 1849-1860.
PubMed
11) 後藤信哉. 臨床現場におけるアスピリン使用の実際. 東京 : 南江堂 ; 2006.
 
12) Patrono C, Garcia Rodriguez LA, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005 ; 353 : 2373-2383.
PubMed
13) Van de Werf F, Ludbrook PA, Bergmann SR, et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984 ; 310 : 609-613.
PubMed
14) A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The global use of strategies to
 
15) Goto S, Handa S, Kawai Y, et al. Augmented plasma protein c activity after coronary thrombolysis with urokinase in patients with acute myocardial infarction. Cardiology. 1992 ; 80 : 252-256.
PubMed
16) 後藤信哉, 阿部純久. 半田俊之介, 他. Urokinaseによる冠血栓溶解療法後の凝固, 線溶動態の経時的検討. 呼吸と循環 1992 ; 40 : 89-95.
 
17) Goto S, Toda E. Antiplatelet therapy after coronary intervention in asia and japan : The asian perspective of antiplatelet intervention. Hamostaseologie. 2009 ; 29 : 321-325.
PubMed
18) Goto S, Tamura N, Sakakibara M, et al. Effects of ticlopidine on von willebrand factor-mediated shearinduced platelet activation and aggregation. Platelets. 2001 ; 12 : 406-414.
PubMed
19) Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med 1998 ; 339 : 1665-1671.
 
20) Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC, Jr. Expert consensus document : World heart federation expert consensus statement on antiplatelet therapy in east asian patients with acs or undergoing pci. Nature reviews. Cardiology. 2014 ; 11 : 597-606.
PubMed
21) Daida H, Miyauchi K, Ogawa H, et al. PACIFIC investigators. Management and two-year long-term clinical outcome of acute coronary syndrome in japan : prevention of atherothrombotic incidents following ischemic coronary attack (pacific) registry. Circ J 2013 ; 77 : 934-943.
PubMed
22) Pfisterer ME. Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction : a new red flag is raised. Circulation. 2008 ; 118 : 1117-1119.
PubMed
23) Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007 ; 297 : 1197-1206.
PubMed
24) Jackson SP, Schoenwaelder SM. Antiplatelet therapy : in search of the 'magic bullet'. Nat Rev Drug Discov 2003 ; 2 : 775-789.
PubMed
25) Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (caprie). Caprie steering committee. Lancet 1996 ; 348 : 1329-1339.
 
26) Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet adp receptor targeted by antithrombotic drugs. Nature 2001 ; 409 : 202-207.
PubMed
27) Goto S, Tamura N, Eto K, et al. Functional significance of adenosine 5'-diphosphate receptor (p2y(12)) in platelet activation initiated by binding of von willebrand factor to platelet gp ibalpha induced by conditions of high shear rate. Circulation 2002 ; 105 : 2531-2536.
PubMed
28) Wiviott SD, Braunwald E, McCabe CH, et al. TRITONTIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007 ; 357 : 2001-2015.
 
29) Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 ; 361 : 1045-1057.
PubMed
30) Shiraga M, Miyata S, Kato H, et al. Impaired platelet function in a patient with p2y12 deficiency caused by a mutation in the translation initiation codon. J Thrombo Haemost 2005 ; 3 : 2315-2323.
 
31) ACTIVE Investigators ; Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 ; 360 : 2066-2078.
PubMed
32) Bhatt DL, Fox KA, Hacke W, et al. ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 ; 354 : 1706-1717.
PubMed
33) Morrow DA, Braunwald E, Bonaca MP, et al. ; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 ; 366(15) : 1404-1413.
 
34) Diener HC, Bogousslavsky J, Brass LM, et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (match) : Randomised, double-blind, placebo-controlled trial. Lancet. 2004 ; 364 (9431) : 331-337.
PubMed
35) Bhatt DL, Steg PG, Ohman EM, et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006 ; 295 : 180-189.
PubMed
36) Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUSTIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015 ; 372(19) : 1791-800.
 
37) Uemura N, Sugano K, Hiraishi H, et al. ; MAGIC Study Group. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular japanese patients : the results from the magic study. J Gastroenterol 2014 ; 49 : 814-824.
 
38) Dewilde WJ, Oirbans T, Verheugt FW, et al. ; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : An open-label, randomised, controlled trial. Lancet 2013 ; 381 (9872) : 1107-1115.
PubMed
39) Levine GN, Jeong YH, Goto S, et al. World heart federation expert consensus statement on antiplatelet therapy in east asian patients with acs or undergoing pci. Global heart. 2014 ; 9 : 457-467.
 
40) Kakkar AK, Mueller I, Bassand JP, et al. ; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke : Perspectives from the international, observational, prospective garfield registry. PloS ONE 2013 ; 8(5) : e63479.
PubMed
open occluded coronary arteries in acute coronary syndromes (gusto iib) angioplasty substudy investigators. N Engl J Med 1997 ; 336 : 1621-1628.
 
P.176 掲載の参考文献
1) Collaboration AT. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention ofdeath, myocardial infarction, and stroke in high risk patients. BMJ 2002 ; 324 : 71-86.
 
2) Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983 ; 309 : 396-403.
PubMed
3) Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Commi t tee to Revi se the 2002 Guidel ines for the Management of Patients With Unstable Angina/Non-STElevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007 ; 50 : e1-e157.
 
4) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告) 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版) 2011/12/21 更新版 http://www.j-circ.or.jp/guideline/index.htm
 
5) Wiviott SD, Braunwald E, McCabe CH, et al.TRITONTIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007 ; 357 : 2001-2015.
 
6) Saito S, Ishibashi T, Kimura T, et al. Efficacy and Safety of Adjusted-Dose Prasugrel Compared With Clopidogrel in Japanese Patients With Acute Coronary Syndrome. Circ J 2014 ; 78 : 1684-1692.
 
7) Nakagawa Y, Nobuyoshi M, Yamaguchi T, et al. Efficacy of abciximab for patients undergoing balloon angioplasty : data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT). Circ J 2009 ; 73 : 145-151.
PubMed
8) Oler A, Whooley MA, Oler J, et al. Adding heparin toaspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996 ; 276 : 811-815.
PubMed
9) Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992 ; 327 : 141-145.
PubMed
10) Anand SS, Yusuf S, Pogue J, et al. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction : organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 1998 ; 98 : 1064-1070.
PubMed
11) The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of longterm, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001 ; 37 : 475-484.
PubMed
12) Komocsi A, Vorobcsuk A, Kehl D, et al. Use of newgeneration oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome : systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012 ; 172 : 1537-1545.
PubMed
13) Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012 ; 366 : 9-19.
PubMed
14) Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty : clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992 ; 19 : 926-935.
 
15) Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995 ; 91 : 1676-1688.
PubMed
16) Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996 ; 334 : 1084-1089.
PubMed
17) Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003 ; 349 : 1315-1323.
 
18) McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004 ; 364 : 1519-1521.
PubMed
19) Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007 ; 356 : 1020-1029.
PubMed
20) Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with baremetal stents. N Engl J Med. 2007 ; 356 : 1030-1039.
PubMed
21) Kimura T, Morimoto T, Nakagawa Y, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009 ; 119 : 987-995.
PubMed
22) Antithrombotic trialists' (ATT) collaboration. Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 ; 373 : 1849-1860.
PubMed
23) Yasue H, Ogawa H, Tanaka H, et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol 1999 ; 83 : 1308-1313.
PubMed
24) Hirayama A, Kodama K, Yui Y, et al. Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from the Japan Multicenter Investigation for Cardiovascular Diseases-Mochida [JMIC-M]). Am J Cardiol 2003 ; 92 : 789-793.
PubMed
25) CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 ; 348 : 1329-1339.
 
26) Bhatt DL, Fox KA, Hacke W, et al. for CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354 : 1706-1717.
PubMed
27) Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003 ; 41 : 62S-69S.
PubMed
28) Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome : meta-analysis with estimates of risk and benefit. Ann Intern Med 2005 ; 143 : 241-250.
PubMed
29) Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002 ; 347 : 969-974.
 
30) Dangas GD. Stent thrombosis A clinical perspective J Am Coll Cardiol Intv 2014 ; 7 : 1081-1092.
 
P.185 掲載の参考文献
1) Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000 ; 31(1 Pt 2) : S1-S296.
 
2) Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007 ; 45 Suppl S : S5-S67.
 
3) Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia : revised version. J Vasc Surg 1997 ; 26(3) : 517-538.
PubMed
4) Creager MA, Kaufman JA, Conte MS. Clinical practice. Acute limb ischemia. N Engl J Med 2012 ; 366(23) : 2198-2206.
PubMed
5) van den Berg JC. Thrombolysis for acute arterial occlusion. J Vasc Surg 2010 ; 52(2) : 512-515.
PubMed
6) Soga Y, Iida O, Kawasaki D, et al. Contemporary Outcomes After Endovascular Treatment for Aorto-Iliac Artery Disease. Circ J 2012 ; 76(11) : 2697-2704.
PubMed
7) Jongkind V, Akkersdijk GJ, Yeung KK, et al. A systematic review of endovascular treatment of extensive aortoiliac occlusive disease. J Vasc Surg. 2010 ; 52(5) : 1376-1383.
 
8) European Stroke O, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases : Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries : the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011 ; 32(22) : 2851-2906.
 
9) Reed AB, Conte MS, Donaldson MC, et al. The impact of patient age and aortic size on the results of aortobifemoral bypass grafting. J Vasc Surg 2003 ; 37(6) : 1219-1225.
PubMed
10) Soga Y, Tomoi Y, Sato K, et al. Clinical outcome after endovascular treatment for isolated common femoral and popliteal artery disease. Cardiovasc Interv Ther 2013 ; 28(3) : 250-257.
PubMed
11) Kang JL, Patel VI, Conrad MF,et al. Common femoral artery occlusive disease : contemporary results following surgical endarterectomy. J Vasc Surg 2008 ; 48(4) : 872-877.
PubMed
12) Ballotta E, Gruppo M, Mazzalai F, et al. Common femoral artery endarterectomy for occlusive disease : an 8-year single-center prospective study. Surgery 2010 ; 147(2) : 268-274.
PubMed
13) Soga Y, Iida O, Hirano K, et al. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg 2010 ; 52(3) : 608-615.
 
14) Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol 2012 ; 59(1) : 16-23.
PubMed
15) Klinkert P, Schepers A, Burger DH, et al. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting : five-year results of a randomized controlled trial. J Vasc Surg 2003 ; 37(1) : 149-155.
PubMed
16) Johnson WC, Lee KK. A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization : a prospective randomized Department of Veterans Affairs cooperative study. J Vasc Surg 2000 ; 32(2) : 268-277.
PubMed
17) Lammer J, Zeller T, Hausegger KA, et al. Heparinbonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions : the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol 2013 ; 62(15) : 1320-1327.
 
18) Saxon RR, Chervu A, Jones PA, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease : 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol 2013 ; 24(2) : 165-173 ; quiz 174.
 
19) BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) : multicentre, randomised controlled trial. Lancet. 2005 ; 366(9501) : 1925-1934.
PubMed
20) Azuma N, Uchida H, Kokubo T, et al. Factors influencing wound healing of critical ischaemic foot after bypass surgery : is the angiosome important in selecting bypass target artery? Eur J Vasc Endovasc Surg 2012 ; 43(3) : 322-328.
PubMed
21) Soga Y, Mii S, Aihara H, et al. Comparison of Clinical Outcome After Bypass Surgery vs. Endovascular Therapy for Infrainguinal Artery Disease in Patients With Critical Limb Ischemia. Circulation Journal 2013 ; 77(8) : 2102-2109.
PubMed
22) Bradbury AW, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial : Analysis of amputation free and overall survival by treatment received. J Vasc Surg 2010 ; 51(5 Suppl) : 18S-31S.
 
23) Nolan BW, De Martino RR, Stone DH, et al. Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass. J Vasc Surg 2011 ; 54(3) : 730-735 ; discussion 735-736.
 
24) 古森公浩. 静脈血栓症, 静脈瘤. 堀正二, 永井良三編. 循環器疾患最新の治療 2012-2013. 南江堂, 2012 ; 424-427.
 
25) Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein t hrombosis. Cochrane Database Syst Rev 2014 ; 1 : CD002783.
 
P.193 掲載の参考文献
1) Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975 ; 256 : 495-497.
PubMed
2) Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 2011 ; 118 : 757-765.
PubMed
3) Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012 ; 120 : 3603-3610.
 
4) Peyvandi F, TITAN Investigators, Duby C. Caplacizumab, anti-vWF nanobody potentially changing the treatment paradigm in thrombotic thrombocytopenic purpura : Results of the TITAN trial. The 56th Annual Meeting of American Society of Hematology, San Francisco, Dec 2014.
 
5) Jiao JA, Kelly AB, Marzec UM, et al. Inhibition of acute vascular thrombosis in chimpanzees by an antihuman tissue factor antibody targeting the factor X binding site. Thromb Haemost 2010 ; 103 : 224-233.
PubMed
6) Morris PE, Steingrub JS, Huang BY, et al. A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome. BMC Pulm Med 2012 ; 12 : 5.
 
7) 山下篤, 森島義行, 梅村和夫, 他. SPC委員会活動報告 動物モデル部会 第XI因子阻害薬. 血栓止血誌 2015 ; 26 : 454-458.
 
8) Buller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015 ; 372 : 232-240.
PubMed
9) Mo Y, Yam FK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy 2015 ; 35(2) : 198-207.
PubMed
10) 嶋緑倫. 血友病. 臨床血液 2013 ; 54 : 189-197.
 
11) Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran : functional and structural characterization. Blood 2013 ; 121 : 3554-3562.
 
12) van Ryn J. Pillu H, Gheyleet L, et al. Effect of Dabigatran on the ability to generate fibrin at a wound site and its reversal by idarucizumab, the antidote to dabigatran, in healthy volunteers : An exploratory marker of blood loss. The 87th Scientific Session of American Heart Association, Chicago, Nov 2014.
 
13) Glund S, Stangier J, Schmoh M, et al. Idarucizumab, a specific antidote for dabigatran : immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. The 56th Annual Meeting of American Society of Hematology, San Francisco, Dec 2014.
 
14) Lenting PJ, Donath MJ, van Mourik JA, et al. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 1994 ; 269 : 7150-7155.
PubMed
15) Lapan KA, Fay PJ. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 1997 ; 272 : 2082-2088.
PubMed
16) Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 1998 ; 273 : 19049-19054.
 
17) Soeda T, Nogami K, Nishiya K, et al. The factor VIIIa C2 domain (residues 2228-2240) interacts with the factor IXa Gla domain in the factor Xase complex. J Biol Chem 2009 ; 284 : 3379-3388.
PubMed
18) Takeyama M, Wakabayashi H, Fay PJ. Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase. Biochemistry 2012 ; 51 : 820-828.
 
19) Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012 ; 18 : 1570-1574.
 
20) Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013 ; 8 : e57479.
PubMed
21) Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody (ACE910) : hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost 2014 ; 12 : 206-213.
 
22) Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014 ; 124 : 3165-3171.
 
23) Shima M, Uchida N, Sanbe T, et al. The safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, demonstrated in healthy adults. The 31st World Congress of World Federation of Hemophilia, Melbourne, May 2014.
 
24) Shima M, Hanabusa H, Taki M, et al. Safety and prophylactic efficacy profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, in Japanese hemophilia A patients both without and with FVIII inhibitors : First-in-patient phase 1 study. The 56th Annual Meeting of American Society of Hematology, San Francisco, Dec 2014.
 
25) Erhardtsen E, Ezban M, Madsen MT, et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995 ; 6 : 388-394.
PubMed
26) Hilden I, Lauritzen B, Sorensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012 ; 119 : 5871-5878.
 
27) Hansen L, Petersen LC, Lauritzen B, et al. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor. Thromb Res 2014 ; 133 : 464-471.
PubMed
28) Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia : a randomized first human dose trial. J Thromb Haemost 2015 ; 31 : 745-754.
 
29) 矢田弘史, 野上恵嗣. 血友病に対する治療の進歩 (1) -長時間作用型薬剤・抗体医薬の面から-. 臨床血液 2014 ; 55 : 893-898.
 
30) Igawa T, Ishii S, Tachibana T, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010 ; 28 : 1203-1207.
PubMed
31) Murphy JE, Wang Z, Winter R. Anti-TFPI antibody variants with differential binding across pH range for improved pharmacokinetics. United States patent US 2014/0275493 A1. 2014.
 
P.200 掲載の参考文献
1) Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006 ; 126 : 663-676.
PubMed
2) Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007 ; 131 : 861-872.
PubMed
3) Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008 ; 26 : 101-106.
PubMed
4) CA, Inoue K, Yamashita T, et al. Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 2012 ; 488 : 652-655.
PubMed
5) Bayart E, Cohen-Haguenauer O. Technological overview of iPS induction from human adult somatic cells. Curr Gene Ther 2013 ; 13 : 73-92.
PubMed
6) Kim EM, Manzar G, Zavazava N. Human iPS cellderived hematopoietic progenitor cells induce T-cell anergy in in vitro-generated alloreactive CD8+ T cells. Blood 2013 ; 121 : 5167-5175.
PubMed
7) Kyba M, et al. HoxB4 confers definitive lymphoidmyeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002 ; 109 : 29.
PubMed
8) Lisheng Wang, et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med 2005 ; 201 : 1603.
PubMed
9) Suzuki N, Nakauchi H, et al. Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation. Mol ther 2013 ; 21 : 1424.
PubMed
10) Keyhanian S, Ebrahimifard M, Zandi M. Investigation on artificial blood or substitute blood replace the natural blood. Iranian J Pediatric Hematol Oncol 2013 ; 4(2) : 72.
PubMed
11) Giarattana MC, Rouard H, Dumont A, et al. Proof of principle for transfusion of in vitro generated red blood cells. Blood 2011 ; 118(19) : 5071.
 
12) Chang KH, Bonig H, Papayannopoulou T. Generation and characterization of erythroid cells from human embryonic stem cells and induced pluripotent stem cells : an overview. Stem Cells Int 2011 ; 2011 : Article ID 791604.
 
13) Hirose S, Takayama N, Nakamura S, et al. Immortalization of Erythroblasts by c-MYC and BCL-XL Enables Large-Scale Erythrocyte Production from Human Pluripotent Stem Cells. Stem Cell Reports 2013 ; 1(6) : 499.
 
14) Ochi K, Takayama N, Hirose S, et al. Multicolor staining of globin subtypes reveals impaired globin switching during erythropoiesis in human pluripotent stem cells. Stem Cells Transl Med 2014 ; 3(7) : 792.
PubMed
15) Takayama N, Nishimura S, Nakamura S, et al. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 2010 ; 207(13) : 2817.
PubMed
16) Nakamura S, Eto K, et al. Expandable Megakaryocyte Cell Lines Enable Clinically Applicable Generation of Platelets from Human Induced Pluripotent Stem Cells. Cell Stem Cell 2014 ; 14(4) : 535.
PubMed
17) Vizcardo R, Masuda KY, Yamada D, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells. Cell Stem Cell 2013 ; 12 : 31-36.
 
18) Vierbuchen T, Wernig M, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010 ; 463 (7284) : 1035-1041.
PubMed
19) Batta K, Florkowska M, Kouskoff V, et al. Direct reprogramming of murine fibroblasts to hematopoietic progenitor cells. Cell Rep 2014 ; 9(5) : 1871-1884.
PubMed
20) Ohnishi K, Yamada Y, et al. Premature Termination of Reprogramming In Vivo Leads to Cancer Development through Altered Epigenetic Regulation. Cell 2014 ; 156(4) : 663-677.
PubMed

書評

最近チェックした商品履歴

Loading...